Regeneron Pharma (REGN) PT Lowered to $392 at RBC Capital
Tweet
Share
E-mail
Get Alerts REGN Hot Sheet
Price: $840.84 +3.78%
Rating Summary:
29 Buy, 19 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 9 | New: 24
Rating Summary:
29 Buy, 19 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 9 | New: 24
Join SI Premium – FREE
RBC Capital analyst Kennen MacKay lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $392.00 (from $397.00) while maintaining a Sector Perform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA approves Regeneron's Pasatru for rare bone disorder FOP
- Global Payments (GPN) PT Raised to $102 at RBC Capital
- Bernstein SocGen Group Upgrades Analog Devices (ADI) to Outperform
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
RBC CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
